Most people notice this when air pressure changes rapidly, such as when a plane ascends or descends. This happens because the ...

Respiratory Syncytial Virus RSV is a common respiratory virus primarily affecting young children Here are some remedies to ...

Older people should take a new vaccine to protect them against Respiratory Syncytial Virus (RSV), according to new research ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...

Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...

Leaders from the Pennsylvania Departments of Health and Insurance this week encouraged all Pennsylvanians to stay up to date on their annual vaccinations to protect against flu, COVID-19, and ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Fall brings cooler days and more time indoors. This makes it easier for viruses like influenza, COVID-19 and respiratory ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...

Forecasts suggest respiratory infections will be similar to last year's season. Vaccination rates will be a factor in the ...

Older people should take a new vaccine to protect them against Respiratory Syncytial Virus (RSV), according to new research from the University of Aberdeen and the MRC-University of Glasgow Center ...

caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through 59 who are at increased risk for LRTD caused by RSV. The data were presented as a ...